News Home

Is Inflarx NV (IFRX) a Stock to Watch This Week?

Tuesday, December 08, 2020 02:24 PM | InvestorsObserver Analysts
Is Inflarx NV (IFRX) a Stock to Watch This Week?

The market has been neutral on Inflarx NV (IFRX) stock recently. IFRX gets a Neutral score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,neutral
Inflarx NV has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on IFRX!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With IFRX Stock Today?

Inflarx NV (IFRX) stock is trading at $4.68 as of 2:22 PM on Tuesday, Dec 8, a rise of $0.63, or 15.64% from the previous closing price of $4.05. The stock has traded between $3.93 and $4.75 so far today. Volume today is elevated. So far 875,889 shares have traded compared to average volume of 194,532 shares.

To see InvestorsObserver's Sentiment Score for Inflarx NV click here.

More About Inflarx NV

InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.

Click Here to get the full Stock Score Report on Inflarx NV (IFRX) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App